Design of a new class of orally active fibrinogen receptor antagonists

Journal of Medicinal Chemistry

Volumn 41, Issue 14, 1998, Pages 2492-2502

  Klein, Scott I ^a,e   Molino, Bruce F ^b   Czekaj, Mark ^a   Gardner, Charles J ^a   Chu, Valeria ^a   Brown, Karen ^a   Sabatino, Ralph D ^d   Bostwick, Jeffrey S ^a   Kasiewski, Charles ^a   Bentley, Ross ^a   Windisch, Vincent ^c   Perrone, Mark ^a   Dunwiddie, Christopher T ^a   Leadley, Robert J ^a  

^a SANOFI   (France)

^b Helios Pharmaceuticals   (United States)

^c Absorption Systems   (United States)

^d Behring Diagnostics Inc   (United States)

^e 3 Dimensional Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; MEMBRANE RECEPTOR;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CAUSE OF DEATH; DIASTEREOISOMER; DRUG EFFICACY; DRUG POTENCY; FIBRINOGEN METABOLISM; ORAL DRUG ADMINISTRATION; THROMBOCYTE AGGREGATION;

ADMINISTRATION, ORAL; ANIMALS; BLOOD PLATELETS; CELL ADHESION; DOGS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; OLIGOPEPTIDES; PIPERIDINES; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; STRUCTURE-ACTIVITY RELATIONSHIP; UMBILICAL VEINS;

EID: 15444360964     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9801096     Document Type: Article

References (38)

1. SCRIP 1995, 2024/25, 23.
2. Phillips, D. R.; Charo, I. F.; Parise, L. V.; Fitzgerald, L. A. The Platelet Membrane Glycoprotein IIb-IIIa Complex. Blood 1988, 71, 831-843.
3. Coller, B. S. Platelets and Thrombolytic Therapy. N. Engl. J. Med. 1990, 322, 33-42.
4. (a) Hynes, R. O. Integrins: A Family of Cell Surface Receptors. Cell 1987, 48, 549-554.
5. (b) Ruoslahti, E.; Pierschbacher, M. D. New Perspectives in Cell Adhesion; RGD and Integrins. Science 1987, 238, 491-497.
6. (a) Shebuski, R. J.; Interruption of Thrombosis and Hemostasis by Antiplatelet Agents. Toxicol. Pathol. 1993, 21, 180-189.
7. (b) Barrett, J. S.; Murphy, G.; Peerlinck, K; DeLepeleire, I.; Gould, R. J.; Panebianco, D.; Hand, E.; Deckmyn, H.; Vermylen, J.; Arnout, J. Pharmacokinetics and Pharmacodynamics of MK-383, A Selective Non-peptide Platelet Glycoprotein-IIb/IIIa Receptor Antagonist, In Healthy Men. Clin, Pharmacol. Ther. 1994, 56, 377-388.
8. (c) Tcheng, J. E.; Ellis, S. G.; Kleiman, N. S.; Harrington, R. A.; Mick, M. J.; Navetta, F. I.; Worley, S.; Smith, J. E.; Kereiakes, D. J.; Kitt, M. M.; Miller, J. A.; Sigmon, K. N.; Califf, R. M.; Topol, E. J. Outcome of Patients Treated with the GP IIb/IIIa Inhibitor Integrelin During Coronary Angioplasty: Results of the IMPACT Study. Circulation 1993, 88, 1-595 (Abstract 3200).
9. (d) Theroux, P.; Koui, S.; Knudtson, M. L.; Kells, C.; Naamith, J.; Roy, L.; Dalle, S.; Steiner, B.; Xiao, Z.; Rapold, H. J. A Randomized Double-blind Controlled Trial with the Non-Peptidic Platelet GP IIb/IIIa antagonist Ro 44-9883 in Unstable Angina. Circulation 1994, 90, I-232 (Abstract 1243).
10. (a) Eldred, C. D.; Evans, B.; Hindley, S.; Judkins, B. D.; Kelly, H. A.; Kitchin, J.; Lumley, P.; Porter, B.; Ross, B. C.; Smith, K. J.; Taylor, N. R.; Wheatcroft, J. R. Orally Active Non-Peptide Fibrinogen Receptor (GpIIb/IIIa) Antagonists: Identification of 4-[4-[4-(Aminoiminomethyl)phenyl)-1-piperazinyl)-1-piperidineacetic Acid as a Long-Acting, Broad Spectrum Antithrombotic Agent. J. Med. Chem. 1994, 37, 3882-3885.
11. (b) Nicholson, N. S.; Panzer-Knodle, S. G.; Salyers, A. K.; Taite, B. B.; Szalony, J. A.; Haas, N. F.; King, L. W.; Zablocki, J. A.; Keller, B. T.; Broschat, K.; Engleman, W.; Herin, M.; Jacqmin, P.; Feigen, L. P. SC-54684A: An Orally Active Inhibitor of Platelet Aggregation. Circulation 1995, 92, 403-410.
12. (c) Barrett, J. S.; Gould, R. J.; Ellis, J. D.; Holahan, M. M.; Stranieri, M. T.; Lynch, J. J.; Hartman, G. D.; Ihle, N.; Duggan, M.; Moreno, O. A.; Theoharides, A. D. Pharmacokinetics and Pharmacodynamics of L-703,014, a Potent Fibrinogen Receptor Antagonist, After Intravenous and Oral Administration in the Dog. Pharm. Res. 1994, 11, 426-431.
13. (d) Duggan, M. E.; Naylor-Olsen, A. M.; Perkins, J. J.; Anderson, P. S.; Chang, C. T.-C.; Cook, J. J.; Gould, R. J.; Ihle, N. C.; Hartman, G. D.; Lynch, J. J.; Lynch, R. J.; Manno, P. D.; Schaffer, L. W.; Smith, R. L. Non-peptide Fibrinogen Receptor Antagonists. XX. Design and Synthesis of the Potent, Orally Active Fibrinogen Receptor Antagonist L-734,-217. J. Med. Chem. 1995, 38, 3332-3341.
14. (e) Bondinell, W. E.; Keenan, R. M.; Miller, W. H.; All, F. E.; Allen, A. C.; DeBrosse, C. W.; Eggleston, D. S.; Erhard, K. F.; Haltiwanger, R. C.; Huffman, W. F.; Hwang, S. M.; Jakas, D. R.; Koster, P. F.; Ku. T. W.; Lee, C. P.; Nichols, A. J.; Ross, S. T.; Samanen, J. M.; Valocik, R. E.; Vasko-Moser, J. A.; Venslavsky, J. W.; Wong, A. S.; Yuan, C.-K. Design of a Potent and Orally Active Nonpeptide Platelet Fibrinogen Receptor (GP IIb/IIIa) Antagonist. Bioorg. Med. Chem. 1994, 2, 897-908.
15. (f) Zablocki, J. A.; Rico, J. G.; Garland, R. B.; Rogers, T. E.; Williams, K.; Schretzman, L. A.; Rao, S. A.; Bovy, P. R.; Tjoeng, F. S.; Lindmark, R. J.; Toth, M. V.; Zupec, M. E.; McMackins, D. E.; Adams, S. P.; Miyano, M.; Markos, C. S.; Milton, M. N.; Paulson, S.; Herin, M.; Jacqmin, P.; Nicholson, N. S.; Panzer-Knodle, S. G.; Haas, N. F.; Page, J. D.; Szalony, J. A.; Taite, B. B.; Salyers, A. K.; King, L. W.; Campion, J. G.; Feigen, L. P. Potent in Vitro and in Vivo Inhibitors of Platelet Aggregation Based Upon the Arg-Gly-Asp Sequence of Fibrinogen. (Aminobenzamidino)succinyl (ABAS) Series of Orally Active Fibrinogen Receptor Antagonists. J. Med. Chem. 1995, 35, 2378-2394.
16. (g) Weller, T.; Alig, L.; Beresini, M.; Blackburn, B.; Bunting, S.; Hadvary, P.; Hurzeler Muller, M.; Knopp, D.; Levet-Trafit, B.; Lipari, M. T.; Modi, N. B.; Muller, M.; Refino, C. J.; Schmitt, M.; Schonholzer, P.; Weiss, S.; Steiner, B. Orally Active Fibrinogen Receptor Antagonists. 2. Amidoximes as Prodrugs of Amidines. J. Med. Chem. 1996, 39, 3139-3147.
17. (h) Samanen, J. M.; Ali, F. E.; Barton, L. S.; Bondinell, W. E.; Burgess, J. L.; Callahan, J. F.; Calvo, R. R.; Chen, W.; Chen, L.; Erhard, K; Feuerstein, G.; Keys, R.; Hwang, S.-M.; Jakas, D. R.; Keenan, R. M.; Ku, T. W.; Kwon, C.; Lee, C.-P.; Miller, W. H.; Newlander, K. A.; Nichols, A.; Parker, M.; Peishoff, C. E.; Rhodes, G.; Ross, S.; Shu, A.; Simpson, R.; Takata, D.; Yellin, T. O.; Uzsinskas, I.; Venslavsky, J. W.; Yuan, C.-K.; Huffman, W. F. Potent, Selective, Orally Active 3-Oxo-1,4-benzodiazepine GPIIb/IIIa Integrin Antagonists. J. Med. Chem. 1996, 39, 4867-4870.
18. (i) Simpfendorfer, C.; Kottke-Marchant, K.; Topol, E. J. First Experience With Chronic Platelet GPIIb/IIIa Receptor Blockade: A Pilot Study of Xemlofiban an Orally Active Antagonist in Unstable Angina Patients Eligible for PTCA. J. Am. Coll. Cardiol. 1995, 27, 242A (Abstract 969-110).
19. (j) Xue, C.-B.; Rafalski, M.; Roderick, J.; Eyermann, C. J.; Mousa, S.; Olson, R. E.; DeGrado, W. F. Design, Synthesis and In Vitro Activities of a Series of Benzimidazole/Benzoxazole Glycoprotein IIb/IIIa Inhibitors. Bioog, Med. Chem. Lett. 1996, 6, 339-344.
20. Lazer, E. S.; Miao, C. K.; Wong, H.-C.; Sorcek, R.; Spero, D. M.; Gilman, A.; Pal, K.; Behnke, M.; Graham, A. G.; Watrous, J. M.; Homon, C. A.; Nagel, J.; Shah, A.; Guindon, Y.; Farina, P. R.; Adams, J. Benzoxazolamines and Benzothiazolamines: Potent, Enantioselective Inhibitors of Leukotriene Biosynthesis with a Novel Mechanism of Action. J. Med. Chem. 1994, 37, 913-923.
21. Evans, D. A.; Britton, T. C.; Ellman, J. A.; Dorow, R. L. The Asymmetrie Synthesis of α-Amino Acids. Electrophilic Azidation of Chiral Imide Enolates, a Practical Approach to the Synthesis of (R)- and (S)-α-Azido Carboxylic Acids. J. Am. Chem. Soc. 1990, 112, 4011-4030.
22. Ishizumi, K.; Koga, K.; Yamada S.-I. Chemistry of Sodium Borohydride and Diborane IV. Reduction of Carboxylic Acids to Alcohols with Sodium Borohydride Through Mixed Carbonic-Carboxylic Acid Anhydrides. Chem. Pharm. Bull. 1968, 16, 492-497.
23. Miller, A. E.; Bischoff, J. J. A Facile Conversion of Amino Acids to Guanidino Acids. Synthesis 1986, 9, 777-779.
24. 50 values for the inhibition of ADP-induced aggregation of canine platelets with those given in Table 2. Compound 17, 52 nM.; compound 21, 60 nM.; compound 23, 102 nM.
25. Klein, S. I.; Molino, B. F.; Chu, V.; Ruggeri, Z.; Czekaj, M.; Gardner, C. J.; Newman, J.; Barrett, J. A. Novel RGD Analogues as Antithrombotic Agents. In Peptides 1990, Proceedings of the Twenty-first European Peptide Symposium;, Giralt, E., Andreu, D., Eds.; ESCOM Science Publishers: Leiden, 1991; pp 374-375.
26. Folts, J. D. An In-Vivo Model of Experimental Arterial Stenosis, Intimal Damage, and Periodic Thrombosis. Circulation 1991, 83, IV-3-IV-14.
27. Klein, S. I.; Molino, B. F.; Czekaj, M.; Gardner, C. J. Antithrombotic Peptides and Pseudopeptides. U.S. Patent 5,051,405 1991.
28. Hartman, G. D.; Egbertson, M. S.; Halczenko, W.; Laswell, W. L.; Duggan, M. E.; Smith, R. L.; Naylor, A. M.; Manno, P. D.; Lynch, R, J.; Zhang, G.; Chang, C.; Gould, R. J. Non-Peptide Fibrinogen Receptor Antagonists. 1. Discovery and Design of Exosite inhibitors. J. Med. Chem. 1992, 35, 4640-4642.
29. For example, compare the following two compounds, which are equipotent in vitro: Equation Presented
30. Ruoslahti, R. Integrins. J. Clin. Invest. 1991, 87, 1-5.
31. Van Mourik, J. A.; Von Den Borne, A. E. G.; Giltay, J. G. Pathophysiological Significance of Integrin Expression by Vascular Endothelial Cells. Biochem. Pharm. 1990, 39, 233-239.
32. (a) Marguerie, G. A.; Plow, E. F.; Edington, T. S. Human Platelets Possess an Inducible and Saturable Receptor Specific for Fibrinogen. J. Biol Chem. 1979, 254, 5357-5363.
33. (b) Ruggeri, Z. M.; DeMarco, L.; Gatti, L.; Bades, R.; Montgomery, R. R. Platelets Have More Than One Binding Site for Von Willebrand Factor. J. Clin. Invest. 1983, 72, 1-12.
34. Born, G. V. R. Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal. Nature 1962, 194, 927-929.
35. Plow, E. F.; Pierschbacher, M. D.; Ruoslahti, E.; Marguerie, G. A.; Ginsberg, M. H. The Effect of Arg-Gly-Asp Containing Peptides on Fibrinogen and Von-Willebrand Binding to Platelets. Proc. Natl. Acad. Sci, U.S.A. 1985, 02, 8057-8061.
36. (a) Hawiger, J.; Timmons, D. In Methods In Enzymology; Hawiger, J., Ed.; Academic Press: New York, 1992; pp 228-243.
37. (b) Fraker, P. J.; Speck, J. C. Protein and Cell Membrane Iodinations with a Sparingly Soluble Chloroamide, 1,3,4,6-Tetrachloro-3a,6a-diphenylglycoluril. Biochem. Biophys. Res. Commun. 1978, 80, 849-857.
38. Ruoslahti, E.; Engvall, E. Two Active Sites with Different Characters in Fibronectin. FEBS Lett. 1979, 97, 221-224.